We are live on ! Find out more
FLNA icon

Filana Therapeutics

26 hedge funds and large institutions have $4.07M invested in Filana Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

0% more capital inflows, than outflows

Capital inflows: $195K | Capital outflows: $195K

0.06% more ownership

Funds ownership: 19.41% → 19.47% (+0.06%)

4% less funds holding

Funds holding: 27 → 26 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
9
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

FLNA Hedge Fund Activity: Q2 2019 in Review

26 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2019, worth a combined $4.07M — down 5.9% from $4.33M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of FLNA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $112K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $51K sold.

  • 26 institutional investors held Filana Therapeutics (FLNA) as of Q2 2019, down from 27 in Q1 2019.
  • Funds reported $4.07M of Filana Therapeutics stock for Q2 2019, down 5.9% quarter-over-quarter.
  • 3 funds opened new Filana Therapeutics positions in Q2 2019 and 4 closed out, a net change of -1 holder.
  • The largest Filana Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $112K added.
  • The largest Filana Therapeutics seller in Q2 2019 was Acadian Asset Management, an estimated $51K sold.

Based on aggregated 13F filings for Q2 2019.